Research Article| Volume 25, ISSUE 3, P642-649, March 2016

Phosphodiesterase-5 Inhibitor PF-03049423 Effect on Stroke Recovery: A Double-Blind, Placebo-Controlled Randomized Clinical Trial


      The therapeutic potential of phosphodiesterase-5 inhibitor PF-03049423 was evaluated in a phase 2, multicenter, randomized, double-blind, placebo-controlled study of subjects with acute ischemic stroke (Clinical Trial Registration Information:, unique identifier: NCT01208233;, EudraCT number: 2010-021414-32).

      Materials and Methods

      Subjects (N = 70) received PF-03049423 6 mg (or placebo, N = 67) once daily, orally, commencing between 24 and 78 hours of stroke onset, and continuing for 90 days. Postbaseline efficacy assessments were performed on Days 7, 14, 30, 60, and 90. Modified Rankin Scale (mRS), Barthel Index, National Institutes of Health Stroke Scale, Box and Blocks Test, Hand-Grip Strength Test, 10-Meter Walk Test, Repeatable Battery Assessment of Neuropsychological Status Naming and Coding Subtests, Line Cancellation Test, and Recognition Memory Test were administered to evaluate poststroke recovery. The primary endpoint was the mRS responder rate (score 0-2 at Day 90). The study included a planned interim analysis of efficacy data.


      The primary efficacy analysis using logistic regression showed no statistically significant difference between PF-03049423 6 mg and placebo (responder rate of 42.6% and 46.2%, respectively). Although PF-03049423 showed a satisfactory safety and tolerability profile, no signal of efficacy emerged from any of the outcome measures.


      PF-03049423 showed no therapeutic potential for acute ischemic stroke.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Stroke and Cerebrovascular Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Jauch E.C.
        • Saver J.L.
        • Adams P.A.
        • et al.
        Guidelines for the early management of patients with acute ischemic stroke.
        Stroke. 2013; 44: 870-947
        • Menniti F.S.
        • Ren J.
        • Coskran T.M.
        • et al.
        Phosphodiesterase 5A inhibitors improve functional recovery after stroke in rats: optimized dosing regimen with implications for mechanism.
        J Pharmacol Exp Ther. 2009; 331: 842-850
        • Zhang R.
        • Wang Y.
        • Zhang L.
        • et al.
        Sildenafil (Viagra) induces neurogenesis and promotes functional recovery after stroke in rats.
        Stroke. 2002; 33: 2675-2680
        • Li L.
        • Jiang Q.
        • Zhang L.
        • et al.
        Angiogenesis and improved cerebral blood flow in the ischemic boundary area detected by MRI after administration of sildenafil to rats with embolic stroke.
        Brain Res. 2007; 1132: 185-192
        • Bednar M.M.
        The role of sildenafil in the treatment of stroke.
        Curr Opin Investig Drugs. 2008; 9: 754-759
        • Boolell M.
        • Allen M.J.
        • Ballard S.A.
        • et al.
        Sildenafil: an orally active type 5 cyclic GMP specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction.
        Int J Impot Res. 1996; 8: 47-52
        • Brott T.G.
        • Adams H.P.
        • Olinger C.P.
        • et al.
        Measurements of acute cerebral infarction: a clinical examination scale.
        Stroke. 1989; 20: 864-870
        • van Swieten J.C.
        • Koudstaal P.J.
        • Visser M.C.
        • et al.
        Interobserver agreement for the assessment of handicap in stroke patients.
        Stroke. 1988; 19: 604-607
        • Mahoney M.I.
        • Barthel D.W.
        Functional evaluation: the Barthel Index.
        Md State Med J. 1965; 14: 61-65
        • Mathiowetz V.
        • Volland G.
        • Kashman N.
        • et al.
        Adult norms for the Box and Block Test for manual dexterity.
        Am J Occup Ther. 1985; 39: 386-391
        • Randolph C.
        Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
        The Psychological Corporation, San Antonio: Harcourt, TX1998
        • Stone S.P.
        • Wilson B.
        • Wroot A.
        • et al.
        The assessment of visuo-spatial neglect after acute stroke.
        J Neurol Neurosurg Psychiatry. 1991; 54: 345-350
        • The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group
        Tissue plasminogen activator for acute ischemic stroke.
        N Engl J Med. 1995; 333: 1581-1588
        • Hacke W.
        • Kaste M.
        • Fieschi C.
        • et al.
        Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS).
        J Am Med Assoc. 1995; 274: 1017-1025
        • Krams M.
        • Lees K.
        • Hacke W.
        • et al.
        Acute stroke therapy by inhibition of neutrophils (ASTIN) an adaptive dose-response study of UK-279,276 in acute ischemic stroke.
        Stroke. 2003; 34: 2543-2548
        • Kroenke K.
        • Strine T.W.
        • Spitzer R.L.
        • et al.
        The PHQ-8 as a measure of current depression in the general population.
        J Affect Disord. 2009; 114: 163-173
        • Hermann D.M.
        • Chopp M.
        Promoting brain remodelling and plasticity for stroke recovery: therapeutic promise and potential pitfalls of clinical translation.
        Lancet Neurol. 2012; 11: 369-380